[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patients-reported-outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patients-reported-outcomes":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100636817",false,"NCT07570615","Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension","Development and Validation of a Chinese Patient-Reported Outcome Measure for Quality of Life in Pulmonary Arterial Hypertension Patients","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed with pulmonary arterial hypertension\n* Able to read and complete questionnaires\n* Provided informed consent\n\nExclusion Criteria:\n\n* Severe physical condition preventing participation\n* History of psychiatric disorders or current use of psychiatric medication\n* Pregnancy or lactation\n* Any condition preventing completion of questionnaires","ALL","18 Years",{"count":18,"type":19},300,"ESTIMATED","OBSERVATIONAL","This study aims to develop and validate a culturally appropriate, reliable, and clinically applicable patient-reported outcome (PRO) instrument to assess quality of life in patients with pulmonary arterial hypertension (PAH) in China.\n\nThe study includes two phases: (1) scale development using literature review, Delphi expert consultation, and patient interviews; and (2) multicenter prospective observational validation to evaluate reliability, validity, and responsiveness.\n\nThe final scale is expected to support clinical assessment, treatment monitoring, and health policy decision-making.",[23,24,25],"Pulmonary Arterial Hypertension (PAH)","Quality of Life","Patients Reported Outcomes","NOT_YET_RECRUITING","2026-04-30",{"date":29,"type":30},"2026-05-06","ACTUAL",{"date":27,"type":19},{"date":33,"type":19},"2029-04-30",{"name":35,"class":36},"Chinese Pulmonary Vascular Disease Research Group","OTHER",""]